CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Ueno M, Takeda H, Takai A, Morimura H, Nishijima N, Iwamoto S, Okuyama S, Umeda M, Seta T, Ikeda A, Goto T, Miyamoto S, Kayahara T, Uenoyama Y, Matsumura K, Nakano S, Mishima M, Inuzuka T, Eso Y, Takahashi K, Marusawa H, Osaki Y, Hatano E, Seno H.
Ueno M, et al. Among authors: goto t.
J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150-7. Online ahead of print.
J Gastroenterol. 2024.
PMID: 39289234